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Alzheimer’s disease is a devastating neurological disorder. The role of hyperexcitability in the
disease’s cognitive decline is not completely understood. In this issue of Neuron, Palop et al. report
both limbic seizures and presumed homeostatic responses to seizures in an animal model of
Alzheimer’s.Alzheimer’s disease (AD) is the most
common cause of dementia, or loss
of intellectual function, among people
aged 65 and older. This loss of cogni-
tive function is the most devastating
feature of AD, and the progressive fail-
ures of declarative and nondeclarative
memory are attributed to the dysfunc-
tion of nerve cells in entorhinal-hippo-
campal circuitry. Currently approved
treatments for AD are either cholines-
terase inhibitors or the N-methyl-D-
aspartate (NMDA) blocker memantine.
Unfortunately, the cognitive benefits of
these drugs have been modest, and
they are not aimed at the essential
causes of AD. Understanding the cel-
lular and molecular mechanisms un-
derlying the cognitive impairments in
AD may lead to better forms of treat-
ment for the debilitating aspects of
this disease.
Converging lines of evidence sup-
port the hypothesis that accumulation
of the amyloid peptides (Ab) contrib-
utes to the pathogenesis of AD (Walsh
and Selkoe, 2004). Ab is formed after
sequential cleavage of the amyloid pre-
cursor protein (APP), a transmembrane
glycoprotein of undetermined func-
tion. Familial autosomal-dominant mu-
tations in APP cause hereditary early-
onset Alzheimer’s disease (FAD), likely
as a result of altered proteolytic pro-
cessing and the production of aberrant
amyloid peptides (Goedert and Spillan-
tini, 2006). The progressive accumula-
tion of Ab in brain regions such as the
hippocampus is theorized tocontributeto the cognitive decline in AD. Here,
Palopetal. (2007) report that transgenic
overexpression of Ab peptide causes
epileptiform activity within the entorhi-
nal-hippocampal circuitry. They pro-
pose that the epileptiform activity to-
gether with homeostatic responses to
this epileptiform activity may contrib-
ute to dysfunction of the circuitry that
underlies memory formation.
The authors study several lines of
transgenic mice overexpressing a mu-
tant form of human APP (hAPPFAD).
When overexpressed in mice, hAPPFAD
is sufficient to recapitulate some of the
biochemical and behavioral features of
AD. Most importantly, these animal
models exhibit impairments in learning
and memory. Palop et al. (2003) previ-
ously reported reduced expression of
calbindin, a calcium binding protein,
in the dentate granule cells of hippo-
campus of hAPPFAD mice as well as in
humans with AD. Here, the authors
confirm these observations and fur-
ther report increases in neuropeptide
Y (NPY) immunoreactivity in the mossy
fiber axons and cell bodies of the den-
tate granule cells (DGCs) and in the
molecular layer of the dentate gyrus
of the hAPPFAD mice. The colocaliza-
tion of the NPY with somatostatin im-
munoreactive fibers in the molecular
layer suggests localization to axons
originating from inhibitory interneurons
of the dentate hilus, as well as termina-
tion of these inhibitory afferents on the
dendrites of the granule cells. Axonal
sprouting of the excitatory granuleNeuron 55, Sepcells was also identified in which their
mossy fiber terminals decorated pre-
sumed GABAergic interneurons, sug-
gesting enhanced recurrent inhibition
of the granule cells themselves. Con-
sistent with the predictions of the im-
munohistochemical findings, whole-
cell patch-clamp recordings revealed
increased frequency and amplitude of
mIPSCs in hippocampal slices isolated
from the hAPPFAD compared to control
mice. Analyses of multiple transgenic
lines correlated these findings with ac-
cumulation of Ab peptide rather than
with plaques or APP itself.
What might cause these interesting
plasticities of the dentate granule
cells? Previous observations by other
investigators raised the possibility
that both the immunohistochemical
and electrophysiological abnormalities
of the granule cells reflected homeo-
static responses to recurrent limbic
seizures. That is, Tonder et al. (1994)
reported identical plasticities of NPY
and calbindin immunoreactivity in the
dentate gyrus 1 day, but not 1 month,
following recurrent seizures in the kin-
dling model and proposed that this
represented homeostatic responses
to the recurrent seizures. Likewise, in-
creased frequency and amplitude of
mIPSCs were found in the dentate
granule cells in slices isolated one
day following recurrent seizures in the
kindling model (Nusser et al., 1998).
As predicted, Palop et al. (2007) dis-
covered impressive epileptiform activ-
ity in hAPPFAD, but not control mice,tember 6, 2007 ª2007 Elsevier Inc. 677
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Previewsusing video-EEG monitoring. The epi-
leptiform activity included frequent
interictal (between seizure) spikes as
well as limbic seizures. Importantly,
the behaviors of the limbic seizures
consisted merely of immobility, rather
than overt tonic or clonic contractions
of musculature typical of seizures pro-
pagating widely throughout the brain.
Together with the findings of Tonder
et al. (1994) and Nusser et al. (1998),
this strongly supports the authors’ as-
sertion that the immunohistochemical
and electrophysiological abnormalities
represent homeostatic responses to
the increased neuronal excitability evi-
denced by both interictal abnormalities
and frank seizure activity.
The authors advance an interesting
idea, namely that both the recurrent
seizure activity and homeostatic re-
sponses to this seizure activity con-
tribute to malfunction of the entorhi-
nal-hippocampal circuitry, specifically
to some of the memory impairments
of the hAPPFAD mice and possibly in
AD in humans as well. This idea is
both eminently plausible and testable
in the hAPPFAD mice. That is, distinct
antiseizure drugs can be administered
chronically with the expectation of
suppressing both recurrent seizure ac-
tivity as well as interictal epileptiform
abnormalities. The key question is
whether inhibiting the epileptiform ac-
tivity in the hAPPFAD prevents these
immunohistochemical and electro-
physiological abnormalities in the678 Neuron 55, September 6, 2007 ª200dentate gyrus and, most importantly,
whether this improves cognitive func-
tion in the hAPPFAD mice.
If successful, such a finding in the
hAPPFAD mice would raise the possi-
bility that similar treatments may bene-
fit cognitive function in humans with
AD. Here the question arises as to
how commonly limbic seizures and
epileptiform EEG activity are associa-
ted with AD in humans. Certainly, the
subtlety of nonconvulsive limbic sei-
zures obscures their detection in some
instances in humans, and one could
imagine even greater problems with
detection in a cognitively impaired in-
dividual. That said, epileptiform abnor-
malities on EEG and complex partial
seizures are uncommon features of
sporadic Alzheimer’s disease, at least
in its early stages, afflicting perhaps
10%–20% of patients (Lehtovirta
et al., 1996; Hesdorffer et al., 1996).
The occurrence of complex partial
seizures may be substantially higher
in some familial forms of AD (Cabrejo
et al., 2006; Takao et al., 2001). It
seems plausible that the phenotype
of hAPPFAD mice more accurately mir-
rors that of rare familial forms with APP
mutations than sporadic AD. If care-
ful video-EEG monitoring of patients
with rare familial forms of AD reveal
epileptiform activity, this would war-
rant careful study to determine
whether pharmacological inhibition of
increased excitability improves cogni-
tive function.7 Elsevier Inc.ACKNOWLEDGMENTS
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